

## SUMMARY OF EXTRAMURAL SUPPORT


The record of extramural support is an especially noteworthy accomplishment of faculty actively engaged in research in the College of Medicine. Although only the principal investigator is listed on the summary report, many projects involve other faculty as co-investigators on grants. This valued practice is highly encouraged by the administration. Funding for the 1999-2000 academic year includes \$17,963,523 and \$2,467,596 administered through the University's Office of Sponsored Programs and the South Alabama Medical Science Foundation, respectively.

### EXTRAMURAL FUNDS

#### Totals for Recent Years

1990	\$ 10,658,000
1991	13,275,000
1992	11,563,000
1993	11,223,000
1994	11,859,000
1995	14,272,462
1996	16,507,457
1997	14,891,699
1998	18,338,972
1999	19,108,225
2000	20,431,119

## College of Medicine Total Annual Extramural Funds From All Sources



**EXTRAMURAL FUNDING  
(OCTOBER 1, 1999-SEPTEMBER 30, 2000)**

**BIOCHEMISTRY AND MOLECULAR BIOLOGY**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEARS TOTAL FUNDING</u>
Nathan Aronson	Structure and Mechanisms of a Family of 18 Chitinases	NIH -- Subcon Duquesne Univ	\$ 148,066
Sailen Barik	Gene Expression of Human Respiratory Syncytial Virus	NIH	110,352
	Signal Transduction in Plasmodium	Burroughs Wellcome Fund	50,000
	Reversible Protein Phosphorylation in Apicomplexans	NIH	273,897
Jane Funkhouser	Alveolar Epithelial Cell Ectopeptidases: A Possible Role In Regulating the Cytokine Cascade	Am Heart Assn SE Affiliate	35,000
James W. Gaubatz	Dietary Mutagens & DNA Damage in Cardiac Myocytes	Am Heart Assn SE Affiliate	35,000
	Dietary Mutagens and Breast Cancer	NIH	169,127
Richard E. Honkanen	Mechanisms of Tumor Promotion and Carcinogenesis	NIH	231,522
	Mechanisms of Cardioprotective Agents in Ischemic Myocytes	NIH	205,966

**BIOCHEMISTRY AND MOLECULAR BIOLOGY (CONT)**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Richard E. Honkanen	The Role of Protein Phosphatase 5 on Glucocorticoid Signaling [Predoctoral Fellowship for John Rodriguez]	NIH	\$ 17,681
Madhavan G. Nair	Cancer Chemotherapy: New Folate Analogs	NIH	185,582
	Cellulose Research Project	Leroy Smith, Inc.	12,500
			<u>\$ 1,474,693</u>

167

**BIOTECHNICAL SERVICES**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Raymond Hester	Leica TCS SP Spectral Confocal Microscope	NCRR	\$ 336,843
			<u>\$ 336,843</u>

**CELL BIOLOGY AND NEUROSCIENCE**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Yogendra M Bhatnagar	Comprehensive Sickle Cell Core Lab*	NIH	\$ 88,404
Stuart D. Critz	Rapid Detection of Brevetoxin and Ciguatoxin Using Recombinant NA+ Channels	USDA	45,016
	Mitochondrial KATP Channels and Ischemic Preconditioning	Am Heart Assn	54,674
Anthony L. Gard	Trophic Determinants of Oligodendrocyte Development	NIH	194,995
	Lipid Peroxidation Damage in Oligodendrocytes: Role of 4-Hydroxynonenal	Nat Multiple Sclerosis Soc	90,140
	Mediators of Oxidative Damage in Oligodendrocytes	NIH	249,643
Steven R. Goodman	The Molecular Defect(s) Within the Spectrin Membrane Skeleton of Irreversibly Sickled Cells*	NIH	102,491
	Comprehensive Sickle Cell Administrative Core*	NIH	324,688
	Programs for Individuals With Sickle Cell Disease To Promote Positive Outcomes*	NIH (Subcon-Awarded Sickle Cell Dis Assoc)	153,299
	Brain Spectrin and Synaptic Transmission	NIH	233,363

**CELL BIOLOGY AND NEUROSCIENCE (CONT)**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Susan P. Ledoux	Repair of DNA Damage Induced by Environmental Agents	NIH	\$ 258,870
	Repair of DNA Damage Induced by Environmental Agents [Career Development Award]	NIH	67,500
Betty S. Pace	Mechanisms Involved in the Induction of Fetal Hemoglobin	NIH	133,650
	Strategies for Fetal Hemoglobin Induction in Sickle Cell Disease Using Novel Stage Specific Transcription Factors	NIH	25,000
	Novel Mechanism for Globin Gene Silencing During Alternate Lineage Commitment*	NIH	73,241
Gan Wang	Oligonucleotide-Mediated Gama-Globin Gene Activation for Sickle Cell Disease	March of Dimes	50,000
	Transcription-Coupled DNA Repair and Genetic Instability	NIH	212,302
	Oligonucleotide-Based Gene Therapy for Sickle Cell Anemia (Scholars Program)*	NIH	115,600
	Peptide Nucleic Acids (PNA)-Mediated Gene Expression and Gene Therapy	NIH	175,092
Glenn L. Wilson	Environmental Beta Cell Toxins--Mechanisms of Action	NIH	243,293
	Gene Specific Mutations in Skin	NIH (Subcon Ohio State)	66,903

**CELL BIOLOGY AND NEUROSCIENCE (CONT)**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Glenn L. Wilson	Altering Cell Survival by Modulating Levels of Mitochondrial DNA Repair Enzymes	DOD (US Army Concept Award)	\$ 68,245
	Oxidative Damage and Repair in Neuronal mtDNA	NIH	240,331
			<u>\$ 3,266,740</u>

**CHARLES M. BAUGH BIOMEDICAL LIBRARY**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Judy F. Burnham	Exhibiting at State Health Professional Association Meetings	NLM/UMHSL Subcon -- Univ of Maryland	\$ 3,000
			<u>\$ 3,000</u>

**COMPARATIVE MEDICINE**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Christian R. Abee	Squirrel Monkey Breeding and Research Resource	NIH	\$ 606,174
	Experimental Emphysema: Studies on Remediation	NIH -- Subcon Georgetown Univ	69,741
	Squirrel Monkey Breeding Colony -- Malaria Study	CDC	59,280
	Experimental Creutzfeldt-Jacob Disease in the Squirrel Monkey	Baxter HealthCare Corp	777,054
			<hr/>
			\$ 1,512,249

171

**COMPREHENSIVE SICKLE CELL CENTER**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Steven R. Goodman	Comprehensive Sickle Cell Center Program*	NIH	\$1,152,859
			<hr/>
	* Individual projects are listed by Department		\$1,152,859*

**EMERGENCY MEDICINE**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Frank Pettyjohn	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 9 Week Study of BMS/189921 in the Treatment of Mild to Moderate Hypertension	Bristol Myers Squibb	\$ 35,276
	A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel Group Study to Assess the Effectiveness and Health Economic Impact of Oral Factive, 320mg Once Daily for 5 Days Versus Oral Clarithromycin 500mg Twice Daily for 7 Days for the Treatment of Acute Exacerbation of Chronic Bronchitis	SmithKline Beecham	10,648
	A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Long-Term Efficacy Study Trial of Preventing Hypertension Using Candesartan Cilexetil 16mg in Patients With Borderline Hypertension High Normal Blood Pressure	Astra/IBAH	11,050
	A Randomized, Double-Blinded, Parallel-Group, Comparative Study of CS-866, Losartan, Valsartan, and Irbesartan Using Ambulatory Blood Pressure Monitoring in Patients with Essential Hypertension	Concepts in Pharm Resch	8,766
	Evaluation of the Antihypertensive Efficacy of Candesartan Cilexetil in Comparison to Losartan: A Multicenter, Double-Blind, Randomized, Parallel-Group, Forced-Titration Study	Astra Zeneca (IBAH)	36,700
			<u>\$ 102,440</u>



**FAMILY PRACTICE AND COMMUNITY MEDICINE**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEARS TOTAL FUNDING</u>
Kelly Derbin	Predoctoral Training in Family Medicine	HRSA, BHP	\$ 129,600
	NHSC Search Program	HRSA (ADPH)	12,000
	Preceptorship Subsidy	AFP, RHB	50,000
R. Allen Perkins	Graduate Training in Family Medicine	HRSA (BHP)	118,787
	Academic Faculty/Rural Physician Reciprocal Mini-Residency Program	ADPH (RHB)	33,000
			<u>\$ 343,387</u>

**MEDICAL GENETICS**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEARS TOTAL FUNDING</u>
Wladimir Wertelecki	Southwest Alabama Integrated Health Services for Genetic Disorders	HRSA (Subcon ADRS)	\$ 173,650
	South Alabama Regional Genetics Program	HRSA (ADPH)	50,000
	Genetics and Mental Health Program	ADMH	137,268
	Ukrainian Birth Defects Project	USAID	499,987
	Alabama Birth Defects Surveillance and Prevention Program	CDC	819,543
			<u>\$1,680,448</u>

**INTERNAL MEDICINE**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
M.A. Alpert	Magnesium in Coronaries (Magic) Trial	NIH - Subcon New Eng Res Inst	\$ 17,500
Michael V. Cohen	Catechols and Adenosine in Myocardial Preconditioning	NIH	203,616
Marcel E. Conrad	Regulators of Iron Absorption	NIH	385,665
	Minority-Based Clinical Oncology Program	NIH	284,788
	The Star Trial	NSABP Fdn	44,600
Jack DiPalma	Comparison of the Clinical Safety and Efficacy of Pantoprazole 10mg, 20mg, or 40mg Once Daily and Placebo in Patients With Symptomatic Erosive Esophagitis	Wyeth-Ayers Res	21,270
	Braintree-Colon Cleansing Comparison	Braintree Labs	11,059
T. Michael Fan	Apoptosis and Ischemic Preconditioning	Am Heart Assn SE Affiliate	30,000
	Suppression of Myocyte Apoptosis by Ischemic/Hypoxic Preconditioning - Role of BCl-2 Phosphorylation	Am Heart Assn	65,000
Joe Hardin	A Multicenter, Randomized, Blinded Placebo Controlled Study to Describe the Long-term Safety of Daily Subcutaneous Injections of Anakinra (r-metHuIL-1ra) in Patients with Rheumatoid Arthritis	AMGEN	15,500

**INTERNAL MEDICINE (CONT)**

**PRINCIPAL INVESTIGATOR**  
Joe Hardin

**YEAR'S TOTAL FUNDING**  
\$ 14,000

**PROJECT TITLE**

**AGENCY**  
Knoll/BASF

A Multicenter, Randomized Double-Blind Placebo-Controlled Phase III Study of the Human Anti-TNF Monoclonal Antibody D1E7 Administered as Subcutaneous Injections to Patients With Active Rheumatoid Arthritis Currently Receiving Treatment With Methotrexate

Johnson Haynes

Acute Lung Injury in Sickle Cell Disease\*

NIH

104,242

Education of Health Professionals\*

NIH

93,164

Jorge Herrera

Chronic Hepatitis Research

Integrated Therapeutics

15,040

Current Treatment in the Management of Viral Hepatitis Pocket Guide

Schering

8,025

Michael Kirkpatrick

An Open, Non-comparative Multicenter Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily for 7 Days for the Treatment of Bacterial Community Acquired Pneumonia in Adults

Smith-Kline Beecham

6,350

Candace C. McCombs

Peer Reviewed Grants Program

Sequella Global Tuberculosis Fdn

72,109

Clara Massey

A Pilot Study to Assess Transesophageal Echocardiography as a Methodology to Follow Resolution of Left Atrial Thrombi in Subjects Receiving Warfarin or H 376/95

Astra/Covance

5,000

**INTERNAL MEDICINE (CONT)**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEARS TOTAL FUNDING</u>
Joseph Michalski	OAK9801, A Study of the Safety and Efficacy of Intra-articular ORTHOVISC Sodium Hyaluronate Injections in Providing Symptomatic Relief of Osteoarthritis of the Knee	Anika	\$ 50,766
	OAK9901, ORTHOVISC Extension Agreement	Anika	11,964
Betty Pace/ Johnson Haynes	A Dose-Ranging Study of the Efficacy and Tolerability of Multiple Doses of Cordox as Adjunct Therapy in the Management of an Acute Sickle Related, Painful, Vaso-occlusive Episode	Questcor (Cypros)	7,443
Jack Painter	An Open Study, With Blinded Endpoint Assessment, to Assess the Safety, Tolerability, and the Effect on Coronary Artery Patency of Intravenous AR-C69931MX as Both Monotherapy and Adjunct to Activase in Patients With St-Elevation Myocardial Infarction	Astra/Henry Ford	18,000
Keith Ramsey	Tipranavir: An Open-Label, Randomized Study Comparing Combination Therapy Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-Experienced HIV-1 Patients	Pharmacia & Upjohn	8,612
Jay Umbreit	Regulators of Intestinal Cholesterol Absorption	Am Heart Assn SE Affiliate	30,000
	Inhibition of Intestinal Heme Iron Absorption	NIH (Subcon - Porphyrin Prod)	33,000
			<hr/>
			\$1,556,713

**MICROBIOLOGY/IMMUNOLOGY**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Joseph H. Coggin	Influenza Vaccine Immunotherapy	Miller Fdn	\$ 100,000
David A. Dean	Vascular Smooth Muscle-Specific Gene Therapy Vectors	NIH	178,850
	Nuclear Targeting Vectors for Corneal Gene Therapy	NIH	280,100
John W. Foster	Acid Tolerance Response of Salmonella	NIH	210,459
	The Role of Acid Resistance in Escherichia Coli O157:H7 Colonization and Disease	USDA	78,685
Robert N. Lausch	Corneal Inflammation and Interleukin-10	NIH	265,375
	Role of MIP-2 in HSV-1 Induced Corneal Inflammation	NIH	266,530
John E. Oakes	Corneal Disease -- Mechanisms of Specific Inflammation	NIH	240,005
	Chemokine Gene Regulation in Human Corneal Epithelia	NIH	266,248
Herbert H. Winkler	Permeability of the Epidemic Typhus Rickettsia	NIH	456,749
David O. Wood	Genetic Analysis of Rickettsia Prowazekii	NIH	317,938
	Transport of S-Adenosylmethionine in Rickettsia	NIH	215,470
			<hr/>
			<b>\$ 2,876,409</b>

**NEUROLOGY**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Jane Boggs	Open-Label, Safety Study of Gabapentin as Adjunct Therapy in Children Aged 1 Month Through 4 Years With Seizures Uncontrolled by Current Anticonvulsant Drugs	Parke-Davis (Warner Lambert)	\$ 39,821
	Multicenter, Double-Blind, Randomized, Placebo-Control, Parallel-Group, Monotherapy Trial of Rufinamide in Patients With Recent-Onset Partial Seizures	Novartis	8,109
	Safety and Efficacy of High Versus Low Dose Rufinamide Monotherapy in Patients With Inadequately Controlled Partial Seizures	Novartis	11,558
Jorge Mendizabal	A Multicenter, Double-Blind, Randomized, Parallel Group Study of the Safety and Efficacy of BOTOX Purified Neurotoxin Complex for the Prophylactic Treatment of Migraine Headache	Allergen	16,100
John Rothrock	A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Three Dosages of BOTOX Purified Neurotoxin Complex for the Prophylactic Treatment of Migraine Headaches	Allergen	43,250
	Patient Preference for Migraine Headache Therapy: Imitrex Tablets Versus Current (Non-Triptan) Therapy	GlaxoWellcome	24,850
Richard M Zweifler	Warfarin VS Aspirin Recurrent Stroke Study (WARSS)	NIH -- Subcon Columbia	25,000
	Siblings With Ischemic Stroke Study (SWISS)	NIH -- Subcon Mayo Fdn	10,000

**NEUROLOGY (CONT)**

**PRINCIPAL INVESTIGATOR**  
Richard M. Zweifler

<b><u>PROJECT TITLE</u></b>	<b><u>AGENCY</u></b>	<b><u>YEAR'S TOTAL FUNDING</u></b>
Vitamin Intervention for Stroke Prevention	NIH -- Subcon Bowman-Gray	\$ 53,655
Warfarin VS Aspirin for Intracranial Arterial Stenosis (WSAID)	NIH -- Subcon Emory	40,192
Antiphospholipid Antibodies and Stroke (APASS)	NIH -- Subcon (HFHSC)	1,200
Stroke Outcomes and Neuroimaging of Intracranial Artherosclerosis	NIH -- Subcon Rhode Island Hosp	3,623
A Double-Blind, Placebo-Controlled, Safety, Efficacy, and Dose Response Trial of Three Intravenous Dosages of BMS 204352 in Patients With Acute Stroke	Bristol Myers Squibb	29,800
Mild Induced Hypothermia in Awake, Unanesthetized Health Volunteers	Medivance	9,938
The Effects of 2000mg Citicoline on Clinical Outcome and the Evolution of Lesion Volume in Human Stroke	Interneuron Pharmaceuticals	22,325
A Phase III Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Hu23f2G (LeukArrest) in Patients With Ischemic Stroke	Pharmaceutical Res Assoc	8,500
A Double-Blind, Randomized, Placebo-Controlled Study of Atorvastatin as Prevention of Cerebrovascular Events in Patients With a Previous Transient Ischemic Attack or Stroke	Parke-Davis (Warner Lambert)	20,000
		<u>\$ 367,921</u>

Richard M. Zweifler/  
Jorge Mendizabal

**OBSTETRICS AND GYNECOLOGY**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Susan Baker	Perinatal Outreach Plan for Provider Education and Network Coordinator	ADPH	\$ 79,645
	Use of Valaciclovir Suppressive Therapy for Recurrent Genital Herpes During Pregnancy	UAB Subcontract (Glaxo Wellcome)	23,878
Botros Rizk	Multicenter Efficacy Study Comparing EMD 90 171, a Once a Week Estradiol-Levonorgestrel Combination Transdermal System, With Placebo in the Treatment of Vasometer Symptoms Associated With Menopause	Quintiles/Solvay	15,282
B. Rizk/ A.H. Kirolos	A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel, Multicenter Study to Assess the Safety and Efficacy of 3 1/2-Day Combinations of 17B-Estradiol/Norethindrone Acetate Transdermal Delivery Systems for Relief of Menopausal Vasometer Symptoms and Reduction of Endometrial Hyperplasia	CRA-Wyeth Ayerst	29,237
Ian Thorneycroft	A Prospective, Double-Blind, Randomized Study of the Safety and Efficacy of Lower Doses of Premarin and Medroxyprogesterone Acetate in Postmenopausal Women	Wyeth-Ayerst	34,736
	A Multicenter, Double-Blind, Randomized, Active- and Placebo-Controlled Pilot Trial of the Vasometer Effect of TSE-424 in Nonflushing, Postmenopausal Women	Wyeth-Ayerst	21,620



**OBSTETRICS AND GYNECOLOGY (CONT)**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Ian Thomeycroft	A Prospective, Randomized Study Comparing the Peri-operative Administration of Procrit (Epoetin Alfa) With Iron Supplementation Versus Iron Supplementation Alone in Patients Undergoing Abdominal Hysterectomy or Myomectomy for Benign Gynecologic Disease	Ortho/Phoenix Int	\$ 5,332
			<u>\$ 209,730</u>

**ORTHOPAEDIC SURGERY**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Russell Meldrum	A Randomized, Double-Blind, Comparative Study of H 376/95 and Enoxaparin for the Prevention of Venous Thromboembolism Following Total Hip Arthroplasty	AstraZeneca/IBAH	\$ 6,000
	A Multicenter, Multinational, Randomized, Double-Blind Comparison of Subcutaneous SR90107A/ORG31540 With Enoxaparin in the Prevention of Deep Vein Thrombosis and Symptomatic Pulmonary Embolism After Elective Hip Replacement or a Revision	SANOFI	12,500
	A New Method for Femoral Canal Preparation in Total Hip Revision Surgery	NSF --Subcon UAB	12,500
Prasit Nimityongskul	Evaluation of the Safety Profile of Oral Tramadol Hydrochloride for the Treatment of Painful Conditions in Children and Adolescents Aged Seven to Sixteen Years	R W Johnson	13,546
Albert W. Pearsall	A Biomechanical Comparison of Four Different Tissues for Reconstruction of the Anterior Cruciate Ligament	Regeneration Tech	11,590
	Articular Cartilage Cell Viability Research	Arthrex	10,000
Viorel Raducan	Biomechanical Properties of C1-C2 Interlaminar Claw Fixation for Treatment of C1-C2 Instability	Medtronic, Inc.	6,000
			<hr/>
			\$ 72,136

**PATHOLOGY**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Miguel Pappolla	Melatonin and Antioxidants as Therapeutic Agents in a Transgenic Mouse Model of Alzheimer's Disease	NIH	\$ 50,000
	A Pilot Trial of Long-Term Melatonin in AD	Alzheimer's Assn.	125,000
	Melatonin as a New Anti-Amyloidogenic and Antioxidant Agent	NIH	284,594
	Mindset Limited Research Agreement	Mindset Limited	78,000
David Wells	INDYNE Cooperative Service	Indyne/Information Dynamics	5,305
			<u>\$ 542,899</u>

**PEDIATRICS**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
David Gremse	A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Lamivudine in the Treatment of Pediatric Subjects With Chronic Hepatitis B Virus Infection	GlaxoWellcome	\$ 8,707
	A Study to Evaluate the Effects of Lansoprazole in Pediatric Patients With Esophagitis Treated for Eight To Twelve Weeks	Raycar & Assoc TAP Holdings	50,382
	A Multicenter, Randomized, Single-Blind Study to Evaluate Omeprazole for the Treatment of Clinically Diagnosed GERD in Pediatric Patients Ages 0 Months Through 24 Months, Inclusive	AstraZeneca/ Covance	28,219
	A Multicenter, Open Label Study of the Efficacy and Safety of Exisulind at the Highest Tolerated Dose in Pediatric With Intact Colons and a Diagnosis of Adenomatous Polyposis Coli	Cell Pathways	8,071
Mary Y. Mancao	Southeast Pediatric Aids Clinical Trial Unit	NIH (Subcon UAB)	125,517
Betty Pace	A Study to Assess the Safety, Dose Conversion and Titration of Duragesic in Pediatric Patients With Chronic Pain Requiring Opioid Therapy	Janssen/Quintiles Pacific	6,250
Kenneth Rettig	Genentech Growth Study	Genentech, Inc.	8,895

**PEDIATRICS (CONT)**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Lawrence J. Sindel	Cystic Fibrosis Center Program	Cystic Fibrosis Fdn	\$ 21,922
Franklin Trimm	Neonatal Follow-Up Grant Project	ADPH	50,195
Richard M. Whitehurst	The Effect of Dexamethasone on Neonatal Cardiac Myocyte Ca <sup>2+</sup> Channels and Its Association With Ventricular Hypertrophy	Am Heart Assn SE Affiliate	35,000
			<hr/>
			\$ 343,158

**PHARMACOLOGY**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
June Ayling	Crystallography of Dehydratase/DcOH: A Target of Lung Disease	NASA	\$ 30,000
	Folate/Vitamin Research	Merck	309,278
Michael D. Chinkers	Regulation of the ANP Receptor/Guanylyl Cyclase	NIH	238,775
	Glucocorticoid Receptor Regulation by Protein Phosphatase	NIH	199,254
Mark N. Gillespie	Hypoxic Pulmonary Hypertension and Polyamines	NIH	269,845
	DNA Lesions and Gene Expression in Hypoxic Lung Disease	NIH	259,430
Ming Li	Regulation of T-Type CA2+ Channel By Glucose in Rat Neonatal Myocytes (Fellowship: Min Zhang)	Am Heart Assn SE Affiliate	25,000
	LVA Calcium Channel and Pancreatic Beta Cell Death	NIH	106,043
Jack Olson	Polyamines and Monochrotaline Pneumotoxicity (AHR-F1)	NIH	213,991
	Pulmonary Endothelial Cell Wound Repair and Polyamines	AHA SE Affiliate	60,000
Jonathan C. Scammell	Animal Model of Glucocorticoid Resistance	NIH	202,536
	Experimental Infection of Squirrel Monkey B-Lymphocytic Cell Lines With Creutzfeldt-Jacob Disease	Baxter HealthCare Corp	87,627

**PHARMACOLOGY (CONT)**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Stephen Schaffer	Taurine Depletion and Osmotic Stress: A Model of Cardioprotection	Am Heart Assn	\$ 55,000
	Does Chronic Therapy With Candesartan Prevent Renal Dysfunction in a New Hypertensive Rat Model of Non-Insulin Dependent Diabetes?	AstraZeneca	\$ 30,000
	Effect of Diabetes and Hypertension on Ischemic Injury	NIH	259,763
	Glucose-Induced Protection Against Hypoxia-Induced Apoptosis	Am Heart Assn SE Affiliate	35,000
Troy Stevens	Regulation of Pulmonary Resistance Vessels	NIH (Subcon Wakeforest)	25,288
	Ca2+ Inhibition of cAMP in Lung Endothelial Permeability	NIH	173,549
	Store Operated CA2+ Entry: Lung Endothelial Permeability	NIH	232,146
	Control of Lung Endothelial Cell Membrane Potential by Cyclic Nucleotide Gated Channel: Response to Inflammation (Fellowship: Song Wei Wu, M.D.)	Am Heart Assn SE Affiliate	25,000
W. Joseph Thompson/ S.J. Strada	Endothelial Cell cGMP Receptors and Function	NIH	275,708
W. Joseph Thompson/ S.J. Strada	Cell Pathways Collaborative Research	Cell Pathways	50,000

**PHARMACOLOGY (CONT)**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEARS TOTAL FUNDING</u>
Danna Zimmer	Studies of Interactions Between P53 and S100 Proteins	ACS – Subcon Univ MD	\$ 31,820
	Mechanisms for Fetal Hemoglobin Induction*	NIH	97,730
	Deciphering the Cellular Functions of Aldolase	NIH – Subcon Boston Univ	18,000
			<u>\$3,320,783</u>

**PHYSIOLOGY**

188

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEARS TOTAL FUNDING</u>
Stephen T. Ballard	Pharmacological Model of Cystic Fibrosis Lung Disease	Cystic Fibrosis Fdn	\$ 43,200
	Regional Ion Transport Across Airway Epithelium	NIH	107,890
Joseph N. Benoit	Intestine in Chronic Portal Hypertension	NIH	253,286
	Analysis of Intracellular Calcium and Tension Development in Smooth Muscle of Small Resistance Arteries (Fellowship: Jason Gardner, Ph.D.)	Am Heart Assn SE Affiliate	25,000
	Advanced Cardiovascular Research for Medical Students	NIH	10,800



**PHYSIOLOGY (CONT)**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEARS TOTAL FUNDING</u>
Joseph N. Benoit	Role Collecting Lymphatic Pumps in Prevention of Interstitial Edema	Lymphedema Fdn	\$ 25,000
James M. Downey	Physical Factors and Coronary Flow	NIH	182,209
	BIONA GLP-1 Research	BioNebraska	5,000
	BIPI p38MAPK Research	Boehringer Ingelheim	5,000
James C. Parker	Mechanical Ventilation Induced Lung Injury	Am Heart Assn SE Affiliate	35,000
	Mechanical Injury to Lung Endothelium	NIH	240,237
Aubrey E. Taylor	Evaluation of Segmental Endothelial Permeability in Rat Lung Subjected to Ischemia/Reperfusion (I/R)	Am Heart Assn SE Affiliate	35,000
Mary I. Townsley	Lung Microcirculation With High Vascular Pressures	NIH	223,034
	Regulation of Pulmonary Endothelial Permeability	NIH	227,664
L. Britt Wilson	Spinal Neurochemistry of the Exercise Pressor Reflex	NIH	86,276
	Role of Substance P in the Collaterals Mediating the Pressor Reflex to Static Contraction	Am Heart Assn SE Affiliate	34,357
			<u>\$1,538,953</u>

**RURAL HEALTH**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Regina M. Benjamin	Basic/Core AHEC Grant	HRSA (BHPR)	\$1,384,536
	Alabama AHEC Program	AFP Rural Hlth Bd	10,000
	CME Video Library	Ernest Debakey Charitable Fdn	12,979
	USA Telemedicine Program	HRSA	1,342,500
			<u>\$2,750,015</u>

**SURGERY**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEARS TOTAL FUNDING</u>
Donna L. Dyess	Peripheral Microvascular Permeability Response to Autocoids in Heart Failure: Role of Catecholamines and Prostanoids	Am Heart Assn SE Affiliate	\$ 32,066
Richard P. Gonzalez	A Multicenter, Investigator-Blinded, Randomized Study to Compare the Safety and Efficacy of IV Daptomycin With That of Vancomycin or a Semi-Synthetic Penicillin in the Treatment of Complicated Bacterial Skin and Soft Tissue Infections Due to Gram-Positive Bacteria	Cubist/Advanced Biologies	6,000
	A Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of IV Daptomycin With That of Vancomycin or a Semi-Synthetic Penicillin in the Treatment of Bacteremic Infections Due to Gram-Positive Bacteria	Cubist/Advanced Biologies	7,000
	A Multicenter, Open-Label, Non-Comparative Study to Assess the Safety and Efficacy of IV Daptomycin in the Treatment of Hospitalized Subject With Infections Due to Gram-Positive Bacteria That Are Resistant to Vancomycin, or Who Are Otherwise Refractory to, or Contraindicated for Currently Available Therapy	Cubist/Advanced Biologies	7,000
	Center to Study Rural Vehicular Trauma	DOT	875,000
Seth Izenberg	A Multicenter Phase III Study to Assess the Safety and Efficacy of Bactericidal/Permeability-Increasing Protein (rBP121) in Patients With Hemorrhage Due to Trauma	IBRD Global	26,988

**SURGERY (CONT)**

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Arnold Luterman	A Randomized, Controlled, Within-Patient-Paired Study to Compare the Effectiveness of Transcye and Biobrane in Treatment Mid-Dermal to Indeterminate Depth Burn Wounds	Lilly Res Labs	\$ 11,519
	Clinical Evaluation of Regranex (becaplermin) Gel 0.01% for the Treatment of Full Thickness Diabetic Neuropathic Foot Ulcers	Integra LifeSci Corp	18,000
	Lilly LY333328 Versus Vancomycin in Skin/Skin-Structure Infections	PPD Dev/ (Advance Tissue Sci.)	36,313
	INTEGRA Artificial Skin - Post Approval Study	Ortho-McNeil	11,250
			<u>\$ 1,031,136</u>

**RANKING OF UNITED STATES MEDICAL SCHOOLS  
ACCORDING TO FUNDS AWARDED BY  
NATIONAL INSTITUTES OF HEALTH  
DURING FISCAL YEAR 1999**

The College of Medicine's rank among all U.S. medical schools for fiscal year 1999 was 92nd. Please note that this ranking is for National Institutes of Health funds only, and does not include extramural funding from other granting agencies. Please also note that the information presented here is for FY 1999, because of the delay in receipt of NIH reports.

<u>RANK</u>	<u>INSTITUTION</u>	<u>TOTAL NIH FUNDS</u>
80	Morehouse College School of Medicine	\$ 14,961,058
81	Loyola Univ Chicago Stritch Sch of Med	14,810,919
82	Howard University College of Medicine	14,562,560
83	New York Medical College	14,534,122
84	SUNY Buffalo Sch of Medicine	14,067,195
85	Medical College of Georgia Sch of Med	13,542,274
86	University of South Florida Col of Med	13,404,217
87	University of Puerto Rico Sch of Med	11,924,182
88	SUNY Hlth Scis Ctr Syracuse Col of Med	10,464,858
89	George Washington Univ Sch of Medicine	9,758,393
90	Univ of Missouri Columbia Sch of Med	9,504,330
91	Meharry Medical College Sch of Medicine	9,390,368
<b>92</b>	<b>University of South Alabama Sch of Med</b>	<b>9,171,397</b>
93	University of Louisville Sch of Medicine	9,109,613
94	Albany Medical College of Union Univ	7,886,740
95	University of Nevada Sch of Medicine	7,543,911
96	Univ of Mississippi Sch of Medicine	7,304,793
97	Medical College of Ohio at Toledo	7,277,186
98	Wright State University Sch of Medicine	6,616,834
99	Charles R. Drew University of Med & Sci	6,555,580
100	Michigan State U Col of Human Medicine	6,355,658
101	West Virginia University Sch of Medicine	5,477,433
102	Eastern Virginia Med/Sch Med Col Hamp Rd	5,128,866
103	Finch Univ of Hlth Scis Chicago Med Sch	4,432,542
104	Texas A&M Univ Col of Medicine	4,398,357

<u>RANK</u>	<u>INSTITUTION</u>	<u>TOTAL NIH FUNDS</u>
105	Texas Tech Univ Hlth Scis Ctr Sch of Med	\$ 4,277,925
106	East Carolina University Sch of Med	4,274,489
107	Loma Linda University Sch of Medicine	4,074,124
108	Central U of the Caribe Sch Med of Cayey	3,983,152
109	Creighton University School of Medicine	3,854,264
110	Ponce School of Medicine	3,754,378
111	Southern Illinois Univ Sp Sch of Med	3,138,829
112	Univ of North Dakota Sch of Medicine	3,069,183
113	Univ of Missouri Kansas City Sch of Med	2,851,043
114	Univ of South Carolina Sch of Medicine	2,841,662
115	East Tenn St Univ Quillen Med Col	2,156,991
116	Univ of Hawaii John A Burns Sch of Med	1,895,483
117	Northeastern Ohio Univs College of Med	1,790,118
118	Marshall University School of Medicine	872,878
119	Univ of South Dakota Sch of Medicine	796,299
120	Med Coll of Pennsylvania/Hahnemann Univ	751,328
121	Mercer University School of Medicine	241,059
122	U S Uniformed Services Univ Hlth Scis	186,521
123	Rush Medical College	114,749